InvestorsHub Logo
Followers 138
Posts 23165
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Saturday, 05/16/2020 11:44:58 AM

Saturday, May 16, 2020 11:44:58 AM

Post# of 462564
Anavex knows the results of the PDD trial are GREAT

100% of eligible participants have opted into the open-label extension study as of December 16, 2019




Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical Trial January 27, 2020




both doses have potential to be efficacious, both the medium dose as well as the high dose

.


Good luck and GOD bless,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News